Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
EXEL
EXEL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
EXEL News
Exelixis Posts Strong Earnings—Could New Highs Be on the Horizon?
3d ago
Marketbeat
Exelixis Q4 2025 Earnings Call Highlights
4d ago
seekingalpha
EXELIXIS Q4 ADJUSTED EPS REACHES USD 0.94, BEATING IBES ESTIMATE OF USD 0.79
4d ago
moomoo
Exelixis Q4 Earnings Beat Expectations with Strong Guidance
4d ago
seekingalpha
Exelixis Set to Announce Q4 Earnings on February 10th
5d ago
seekingalpha
Exelixis' NDA for Zanzalintinib Accepted by FDA for Review
Feb 02 2026
Newsfilter
Exelixis and Summit Therapeutics: Promising Drug Candidates Ahead
Feb 01 2026
NASDAQ.COM
Exelixis and Summit Therapeutics: Future Prospects
Feb 01 2026
Fool
Wall Street Analysts Adjust Ratings
Jan 27 2026
Benzinga
10 Healthcare Stocks with A+ EPS Revision Ratings Attracting Investor Attention
Jan 16 2026
seekingalpha
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
Jan 12 2026
Benzinga
Exelixis Provides 2026 Financial Guidance: Anticipates $2.525B to $2.625B in Revenue
Jan 11 2026
Businesswire
Activist Investors Target Signet Jewelers, Natural Gas Services, and Other Stocks
Jan 09 2026
Barron's
Exelixis Collaborates with Natera for STELLAR-316 CRC Study
Jan 08 2026
NASDAQ.COM
Axsome and Exelixis: New Investment Opportunities in Biotech
Jan 08 2026
Fool
Axsome and Exelixis Show Significant Revenue Growth in Biotech Sector
Jan 08 2026
NASDAQ.COM
Show More News
